A novel hyperactive BCR::ABL1 ( e6a3 ) variant confers resistance to combined asciminib plus ponatinib therapy
一种新型高活性 BCR::ABL1 (e6a3) 变体赋予了对阿西米尼联合帕纳替尼治疗的耐药性
期刊:
影响因子:
doi:10.21203/rs.3.rs-9077609/v1
Malekzadeh, Malakeh; Ghimire, Hemendra; Popuri, Karteek; Fujita, Kazuki; Salhotra, Amandeep; Yamauchi, Dave; Chen, Bihong; Froelich, Jerry; Storme, Guy; Stein, Anthony; Beg, Mirza Faisal; Wong, Jeffrey; Malki, Monzr M Al; Hui, Susanta K; Nardi, Valentina; Schwieterman, Joshua; Ansari, Sekhu; Kincaid, Zachary; Azhar, Mohammad; Yousuf, Tahira; Amir, Noor; Khan, Areeba; Kesarwani, Meenu; Ryall, Scott; Brunner, Andrew M; Capilla Guerra, Maria Reyes; Griffin, Gabriel K; Nassar, Nicolas; Daley, George Q; Azam, Mohammad